HMGB1 and Alzheimer disease: Herein, we discuss the pathogenic role of HMGB1 and its principal receptors in AD pathology along with their biomarker potential and the promising clinical outcome of blocking/inhibiting HMGB1, RAGE, and TLR4 in AD experimental studies.